Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
Pneumococcal disease
Type of publications
NITAG documentation (88)
Reports (1)
SAGE documentation (8)
Scientific publications (1)
Systematic reviews (SYSVAC) (168)
Regions
Africa (11)
Americas (52)
Eastern Mediterranean (1)
Europe (39)
South-East Asia (4)
Western Pacific (15)
Diseases
Pneumococcal disease (266)
Chikungunya (9)
Cholera (33)
COVID-19 (1481)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
Methodological quality (AMSTAR 2)
High (9)
Moderate (2)
Low (13)
Critically low (80)
Not applicable (64)
266 results found
2014
∙
Fleming-Dutra, K. E. Conklin, L. Loo, J. D. Knoll, M. D. Park, D. E. Kirk, J. Goldblatt, D. Whitney, C. G. O'Brien, K. L.
Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage
2014
∙
Sudarsanam, T. D. Tharyan, P.
Vaccines for preventing pneumococcal infection in adults. Summary of the evidence and implications for public health programmes
2014
∙
ACIP
ACIP minutes meeting
2014
∙
Conseil Supérieur de la Santé (CSS)
Pneumococcal Vaccine
2014
∙
CFV
recommanda- tions visant à prévenir les maladies invasives à pneumocoques chez les groupes à risque
2014
∙
NACI
Update on the Use of Pneumococcal Vaccines: Addition of Asthma as a High-Risk Condition
2014
∙
ACIP
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years
2013
∙
Schönberger, K. Kirchgässner, K. Riedel, C. von Kries, R.
Effectiveness of 2+1 PCV7 vaccination schedules in children under 2 years: A meta-analysis of impact studies
2013
∙
Davis, S. M. Deloria-Knoll, M. Kassa, H. T. O’Brien, K. L.
Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: Review of evidence on indirect effects
2013
∙
Fischer Walker, C. L. Munos, M. K. Black, R. E.
Quantifying the indirect effects of key child survival interventions for pneumonia, diarrhoea, and measles
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register